Oktar S, Doğru S, Motor S, Demirköse M, Erden E Ş
MD, PhD, Associate Professor in Pharmacology, Department of Pharmacology; University of Health Sciences, Beyhekim Training and Research Hospital, Konya, Turkey.
MD, Assistant Professor in Chest Diseases, Department of Chest Diseases; Gaziantep University, Medical School, Gaziantep, Turkey.
Sovrem Tekhnologii Med. 2024;16(4):55-60. doi: 10.17691/stm2024.16.4.06. Epub 2024 Aug 30.
There are some indications in a few studies on animals and humans that the mucolytic agents N-acetylcysteine and erdosteine have a disruptive effect on the coagulation cascade. This study to examine the effects of both erdosteine and N-acetylcysteine on the coagulation pathway.
The research was conducted on patients treated with N-acetylcysteine (600 mg/day) or erdosteine (600 mg/day) for 7-14 days. To evaluate the coagulation and hemogram parameters, blood samples were taken from patients before treatment and on days 7-14 after starting the treatment. Hemogram and coagulation parameters were measured in the venous blood samples.
The levels of factor II significantly decreased, and the platelet count significantly increased in patients treated with erdosteine. D-dimer levels reduced and factor VII levels increased in patients treated with N-acetylcysteine, but these changes were not significant (p=0.069 and p=0.062, respectively). Other coagulation and hemogram values did not change in both groups. Erdosteine may have a dualistic effect on the coagulation cascade through its different metabolites.
在一些针对动物和人类的研究中有迹象表明，黏液溶解剂N-乙酰半胱氨酸和厄多司坦对凝血级联反应有破坏作用。本研究旨在考察厄多司坦和N-乙酰半胱氨酸对凝血途径的影响。
对接受N-乙酰半胱氨酸（600毫克/天）或厄多司坦（600毫克/天）治疗7至14天的患者进行研究。为评估凝血和血常规参数，在治疗前以及开始治疗后第7至14天采集患者的血样。在静脉血样本中测量血常规和凝血参数。
接受厄多司坦治疗的患者中，凝血因子II水平显著降低，血小板计数显著升高。接受N-乙酰半胱氨酸治疗的患者中，D-二聚体水平降低，凝血因子VII水平升高，但这些变化不显著（分别为p = 0.069和p = 0.062）。两组的其他凝血和血常规值均未改变。厄多司坦可能通过其不同代谢产物对凝血级联反应产生二元效应。
